← Back to Search

Sorilux for Plaque Psoriasis

Phase 4
Waitlist Available
Led By Leon H Kircik
Research Sponsored by Skin Sciences, PLLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screening/baseline, week 2, week 8
Awards & highlights

Study Summary

This study is evaluating whether a combination of two medications may be more effective than either medication alone for treating psoriasis.

Eligible Conditions
  • Plaque Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening/baseline, week 2, week 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and screening/baseline, week 2, week 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of subjects who maintain clear or almost clear on Physician Global Assessment (PGA) at Week 8
Secondary outcome measures
Change in Dermatology Life Quality Index (DLQI) at week 2 and week 8
Change in Total Lesion Severity Score (TLSS) at week 2 and week 8
Change in Visual Analogue Scale (VAS) at week 2 and week 8
+1 more

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: SoriluxActive Control1 Intervention
Calcipotriol Foam (Sorilux Foam) for 6 weeks Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2. Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 6 weeks. SORILUX Foam contains calcipotriene 50 mcg/g.
Group II: Lexette + SoriluxActive Control2 Interventions
Halobetasol Propionate Topical Foam (Lexette Foam) + Calcipotriol Foam (Sorilux Foam) for 2 weeks Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate. Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
Group III: VehiclePlacebo Group1 Intervention
Vehicle Foam for 6 weeks. Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2. Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
Group IV: Lexette + VehiclePlacebo Group2 Interventions
Halobetasol Propionate Topical Foam (Lexette Foam) + Vehicle Foam for 2 weeks Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate. Vehicle Foam would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application.

Find a Location

Who is running the clinical trial?

Skin Sciences, PLLCLead Sponsor
Leon H KircikPrincipal InvestigatorSkin Sciences, PLLC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis
Leon H. Kircik, MD 2021. "Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04571151.
All > Psoriasis > Plaque Psoriasis
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top